Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics

Satoshi Yamasaki, Goichi Yoshimoto, Ryosuke Ogawa, Kenichi Aoki, Masakazu Higuchi, Naoki Harada, Fumito Arima, Seiji Kondo, Fujio Matubara, Tsutomu Takahashi, Naokuni Uike, Toshihiro Miyamoto, Seiichi Okamura, Koichi Akashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The introduction of reduced-intensity conditioning (RIC) regimens has made possible allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML). However, the optimal timing of allo-HCT in these patients and its relative risks and benefits when compared with chemotherapies have not been determined. This retrospective study by the Fukuoka Blood and Marrow Transplant Group compared RIC allo-HSCT with non-transplant therapies, the choice based on donor availability, in AML patients in their first complete remission (CR1). The prognostic value of various patient characteristics and disease-specific variables were investigated in 299 patients aged ≥60 years with AML in CR1. Among the 107 patients aged 60–65 years, 54 of whom received allo-HCT and 53 of whom continued chemotherapies; allo-HCT, adverse-risk group, and hematopoietic cell transplantation-comorbidity index were significant predictors of survival outcomes. Among 192 patients aged ≥66 years deemed ineligible for allo-HCT, relapse and Karnofsky performance status after induction therapy were significant predictors of survival outcomes. Findings from this study may facilitate a new standard of care for older AML patients in CR1 who are considered candidates for allo-HCT.

Original languageEnglish
Pages (from-to)1159-1165
Number of pages7
JournalAnnals of Hematology
Volume94
Issue number7
DOIs
Publication statusPublished - Jul 18 2015

Fingerprint

Cell Transplantation
Acute Myeloid Leukemia
Cytogenetics
Karnofsky Performance Status
Drug Therapy
Survival
Standard of Care
Comorbidity
Retrospective Studies
Bone Marrow
Tissue Donors
Transplants
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics. / Yamasaki, Satoshi; Yoshimoto, Goichi; Ogawa, Ryosuke; Aoki, Kenichi; Higuchi, Masakazu; Harada, Naoki; Arima, Fumito; Kondo, Seiji; Matubara, Fujio; Takahashi, Tsutomu; Uike, Naokuni; Miyamoto, Toshihiro; Okamura, Seiichi; Akashi, Koichi.

In: Annals of Hematology, Vol. 94, No. 7, 18.07.2015, p. 1159-1165.

Research output: Contribution to journalArticle

Yamasaki, S, Yoshimoto, G, Ogawa, R, Aoki, K, Higuchi, M, Harada, N, Arima, F, Kondo, S, Matubara, F, Takahashi, T, Uike, N, Miyamoto, T, Okamura, S & Akashi, K 2015, 'Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics', Annals of Hematology, vol. 94, no. 7, pp. 1159-1165. https://doi.org/10.1007/s00277-015-2338-7
Yamasaki, Satoshi ; Yoshimoto, Goichi ; Ogawa, Ryosuke ; Aoki, Kenichi ; Higuchi, Masakazu ; Harada, Naoki ; Arima, Fumito ; Kondo, Seiji ; Matubara, Fujio ; Takahashi, Tsutomu ; Uike, Naokuni ; Miyamoto, Toshihiro ; Okamura, Seiichi ; Akashi, Koichi. / Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics. In: Annals of Hematology. 2015 ; Vol. 94, No. 7. pp. 1159-1165.
@article{3e85b986fddc4dd08185079daf918bca,
title = "Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics",
abstract = "The introduction of reduced-intensity conditioning (RIC) regimens has made possible allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML). However, the optimal timing of allo-HCT in these patients and its relative risks and benefits when compared with chemotherapies have not been determined. This retrospective study by the Fukuoka Blood and Marrow Transplant Group compared RIC allo-HSCT with non-transplant therapies, the choice based on donor availability, in AML patients in their first complete remission (CR1). The prognostic value of various patient characteristics and disease-specific variables were investigated in 299 patients aged ≥60 years with AML in CR1. Among the 107 patients aged 60–65 years, 54 of whom received allo-HCT and 53 of whom continued chemotherapies; allo-HCT, adverse-risk group, and hematopoietic cell transplantation-comorbidity index were significant predictors of survival outcomes. Among 192 patients aged ≥66 years deemed ineligible for allo-HCT, relapse and Karnofsky performance status after induction therapy were significant predictors of survival outcomes. Findings from this study may facilitate a new standard of care for older AML patients in CR1 who are considered candidates for allo-HCT.",
author = "Satoshi Yamasaki and Goichi Yoshimoto and Ryosuke Ogawa and Kenichi Aoki and Masakazu Higuchi and Naoki Harada and Fumito Arima and Seiji Kondo and Fujio Matubara and Tsutomu Takahashi and Naokuni Uike and Toshihiro Miyamoto and Seiichi Okamura and Koichi Akashi",
year = "2015",
month = "7",
day = "18",
doi = "10.1007/s00277-015-2338-7",
language = "English",
volume = "94",
pages = "1159--1165",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics

AU - Yamasaki, Satoshi

AU - Yoshimoto, Goichi

AU - Ogawa, Ryosuke

AU - Aoki, Kenichi

AU - Higuchi, Masakazu

AU - Harada, Naoki

AU - Arima, Fumito

AU - Kondo, Seiji

AU - Matubara, Fujio

AU - Takahashi, Tsutomu

AU - Uike, Naokuni

AU - Miyamoto, Toshihiro

AU - Okamura, Seiichi

AU - Akashi, Koichi

PY - 2015/7/18

Y1 - 2015/7/18

N2 - The introduction of reduced-intensity conditioning (RIC) regimens has made possible allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML). However, the optimal timing of allo-HCT in these patients and its relative risks and benefits when compared with chemotherapies have not been determined. This retrospective study by the Fukuoka Blood and Marrow Transplant Group compared RIC allo-HSCT with non-transplant therapies, the choice based on donor availability, in AML patients in their first complete remission (CR1). The prognostic value of various patient characteristics and disease-specific variables were investigated in 299 patients aged ≥60 years with AML in CR1. Among the 107 patients aged 60–65 years, 54 of whom received allo-HCT and 53 of whom continued chemotherapies; allo-HCT, adverse-risk group, and hematopoietic cell transplantation-comorbidity index were significant predictors of survival outcomes. Among 192 patients aged ≥66 years deemed ineligible for allo-HCT, relapse and Karnofsky performance status after induction therapy were significant predictors of survival outcomes. Findings from this study may facilitate a new standard of care for older AML patients in CR1 who are considered candidates for allo-HCT.

AB - The introduction of reduced-intensity conditioning (RIC) regimens has made possible allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML). However, the optimal timing of allo-HCT in these patients and its relative risks and benefits when compared with chemotherapies have not been determined. This retrospective study by the Fukuoka Blood and Marrow Transplant Group compared RIC allo-HSCT with non-transplant therapies, the choice based on donor availability, in AML patients in their first complete remission (CR1). The prognostic value of various patient characteristics and disease-specific variables were investigated in 299 patients aged ≥60 years with AML in CR1. Among the 107 patients aged 60–65 years, 54 of whom received allo-HCT and 53 of whom continued chemotherapies; allo-HCT, adverse-risk group, and hematopoietic cell transplantation-comorbidity index were significant predictors of survival outcomes. Among 192 patients aged ≥66 years deemed ineligible for allo-HCT, relapse and Karnofsky performance status after induction therapy were significant predictors of survival outcomes. Findings from this study may facilitate a new standard of care for older AML patients in CR1 who are considered candidates for allo-HCT.

UR - http://www.scopus.com/inward/record.url?scp=84937511253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937511253&partnerID=8YFLogxK

U2 - 10.1007/s00277-015-2338-7

DO - 10.1007/s00277-015-2338-7

M3 - Article

VL - 94

SP - 1159

EP - 1165

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 7

ER -